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A B S T R A C T
A series of aryl and heteroaryl substituted oxychinolin derivatives have been synthesized
and spectral characterizations have been conducted with different modern analytical tech-
niques. The antimicrobial activities of the novel synthesized oxychinolin analogs against
different microbial strains have been screened by agar diffusion method. The compounds
4g and 4h were observed with significant antibacterial activity in comparison to reference
antibiotic (ampicillin) against most of the bacterial pathogens. Compounds
4-((8-hydroxyquinolin-5-yl) diazenyl)-N-(5-methyl isoxazol-3-yl) benzene sulfonamide (4c),
4-((8-hydroxyquinolin-5-yl) diazenyl)-1, 5-dimethyl-2-phenyl-1H-pyrazol-3(2H)-one (4g) and
2-((8-hydroxyquinolin-5-yl)diazenyl) benzoic acid (4h) showed zone of inhibition at MIC level
31.25 μg mL−1 against most of the organisms. The compounds 4g and 4h are observed with
significant wound healing, analgesic and potential antioxidant activity.
© 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of Beni-Suef Uni-
versity. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).
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1. Introduction
Treatment of microbial infections still remains a challenging
job due to increasing number of multidrug resistant micro-
bial pathogens and inclusion of emerging infectious diseases.
Though, development of novel synthetic compounds to deal
with resistant microorganisms has become one of the most
vital spheres of antimicrobial research today, still resistance
of pathogenic bacteria and fungi toward available antimicro-
bial drug is also a worldwide major problem.Therefore, the drug
resistance problem needs continuous discovery of novel an-
timicrobial agents.The misuse of antibiotics is not only abusing
rational use of drugs but also leading toward antibiotic
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resistance. Explosive population growth, improper educa-
tion, lack of proper food and shelter are major social calamities
for the people who are living under poverty line. They even
cannot dream for a healthy hygienic livelihood, while they are
unable to arrange a regular balanced meal and are prone to
various infectious pathogenic diseases. It is the social respon-
sibility to explore less toxic and highly effective drug molecules
in less cost so that everybody can afford. The exploitation of
a simple molecule with different functionalities for the syn-
thesis of hybrid active molecules is a worthwhile contribution
in medicinal chemistry. Oxychinolin is one of the most popular
organic compound that consists of a phenol ring fused to a pyri-
dine ring and is also known as 8-hydroxyquinoline (8-HQ).
Literature survey reveals that 8-hydroxyquinoline derivatives
have been shown to possess various pharmacological actions,
including germicidal and antiseptic (Moness and Christiansen,
1934), antiviral (Kassem et al., 2012), antimicrobial (Abdel-Moty
et al., 2005), antitumor (Sau et al., 2013), anti-inflammatory
(Mostafa et al., 2009), anti-asthmatic and analgesic (Anuradha
et al., 2014), antioxidant, anticancer, anti-neurodegenerative and
anti-diabetic (Veda et al., 2013) activities. It is nontoxic to
humans on oral absorption and inhalation, while azo analogs
are well recognized for their medicinal uses such as antisep-
tics (Browing et al., 1926), antitumor (Sava et al., 1982),
antimicrobial and antioxidant (Sahoo and Sudhir Kumar, 2015).
Therefore it was decided to synthesize and investigate the pos-
sible biological activities of novel oxychinolin derivatives and
to characterize them.
2. Materials and methods
2.1. Chemistry
The chemicals used for present research studies were of syn-
thetic grade; Merck Ltd. and Hi Media Laboratories Pvt. Ltd.,
Mumbai, India. The prepared products were analyzed by JASCO
FT/IR 4100 Spectrophotometer; Bruker 1H NMR 300 MHz using
tetramethyl silane; JASCO V-630 UV-Spectrophotometer;
Shimadzu-Mass spectrometer; Perkin Elmer model 2400 CHNS/O
analyzer; METTLER TOLEDO STARe differential scanning calo-
rimetry system and Elico melting point apparatus.
The synthesis of azo oxychinolin (8-HQ) derivatives (4a–h)
was carried out as described previously (Sahoo et al., 2014)
(Scheme 1).
2.1.1. 4-((8-Hydroxyquinolin-5-yl) diazenyl) benzene
sulfonamide (4a)
Dark red color; yield 90%; Rf; 0.8, mp (°C); 287–290; UV–vis
(λ max, nm, methanol): 398; IR (KBr, γ, cm−1): 3118 (O—H str),
3339, 3236 (NH2 of sulfonamide), 2923 (C=C str. quinolinyl), 1573
(C=N str. quinolinyl), 1503 (—N=N—), 1323 (O—H bend), 1392,
1153 (SO2 str. of sulfonamide), 915 (S—N str), 843 (1,4 disubst.
Ar—H); 1H NMR (DMSO-d6, δ ppm, 300 MHz): 7.52 (s, 2H, SO2NH2),
8.00–8.99 (d, 4H, aryl-H), 9.33 (d, quinolinyl H-2, J = 9.0 Hz), 7.77
(d, quinolinyl H-3, J = 9.0 Hz), 8.13 (d, quinolinyl H-4, J = 8.0 Hz),
7.80 (d, quinolinyl H-6, J = 8.0 Hz), 7.24 (d, quinolinyl H-7,
J = 8.0 Hz); LC–MS (% area); 100; m/z; 329.23 (M + 1); analysis for
C15H12N4O3S: calcd % C, 54.87; H, 3.68; N, 17.06; S, 9.77; found
%: C, 54.84; H, 3.67; N, 17.08; S, 9.75.
2.1.2. 4-((8-Hydroxyquinolin-5-yl) diazenyl) benzene sulfonic
acid (4b)
Orange color; yield 85%; Rf; 0.7, mp (°C); 298–300; UV–vis (λ max,
nm, methanol): 391; IR (KBr, γ, cm−1): 3295, 3150 (O—H str), 1577
(C=N str. quinolinyl), 1509 (—N=N—), 1295 (O—H bend), 1355,
1125 (SO2 str. of sulfonic acid), 915 (S—N str), 843 (1,4 disubst.
Ar—H); 1H NMR (DMSO-d6, δ ppm, 300 MHz): 8.10–8.63 (m, 4H,
aryl-H), 8.95 (d, quinolinyl H-2, J = 9.0 Hz), 7.75 (d, quinolinyl H-3,
J = 9.3 Hz), 8.50 (d, quinolinyl H-4, J = 8.01 Hz), 7.91 (d, quinolinyl
H-6, J = 8.07 Hz), 7.32 (d, quinolinyl H-7, J = 8.03 Hz); LC–MS (%
area); 100; m/z; 328.23 (M-1); analysis for C15H11N3O4S: calcd %
C, 54.71; H, 3.37; N, 12.76; S, 9.74; found %: C, 54.72; H, 3.36; N,
12.78; S, 9.73.
2.1.3. 4-((8-Hydroxyquinolin-5-yl) diazenyl)-N-(5-methyl
isoxazol-3-yl) benzene sulfonamide (4c)
Orange color; yield 92%; Rf; 0.8, mp (°C); 220–223; UV–vis (λ max,
nm, methanol): 403; IR (KBr, γ, cm−1): 3297 (O—H/NH str.), 1616
(C=C str.), 2847 (CH2 str. methyl isoxazolyl), 1573 (C=N str.
Ar/Heteroaryl-NH2
+
4(a-h)
1(a-h)
2(a-h)
Ar; 4-sulfomoyl phenyl-(4a),phenyl 2-sulfonic acid-(4b), 3- nitro phenyl- (4d),2-methoxy phenyl-(4e),
4-bromo,3-methyl phenyl-(4f), 2-carboxy phenyl- (4h).
Heteroaryl; N-(5-methylisoxazol-3-yl)benzene sulfonamide- (4c),4-(1,5 dimethyl-2-phenyl-pyrazol-3-one-(4g)
3
i
Ar/Heteroaryl-N=N-Cl
N
OH
ii
N
OH
N
N
Ar/Heteroaryl
Reaction :- i. NaNO2/ HCl, 0-50 C, diazotization ii. NaOH / acetate buffer 30 min coupling reaction
(Synthesis of 5-heteroaryl/arylazo Oxychinolin analogues)
Scheme 1 – Synthesis of 5-heteroaryl/arylazo oxychinolin analogs.
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quinolinyl), 1506 (—N=N—), 1234 (C—O str.), 1341, 1170 (SO2
str. of sulfonamide), 934 (S—N str.);1H NMR (DMSO-d6, δ ppm,
300 MHz): 2.38 (s, 3H, CH3), 8.0–8.05 (m, 4H, aryl-H), 9.28 (d,
quinolinyl H-2, J = 9.01 Hz), 7.63 (d, quinolinyl H-3, J = 9.05 Hz),
8.03 (d, quinolinyl H-4, J = 8.07 Hz), 8.0 (d, quinolinyl H-6,
J = 8.03 Hz), 7.26 (d, quinolinyl H-7, J = 8.09 Hz), 6.28 (s, 1H,
isoxazolyl); LC–MS (% area); 100; m/z; 410.30 (M + 1); analysis
for C19H15N5O4S: calcd % C, 55.74; H, 3.69; N, 17.11; S, 7.83; found
%: C, 55.72; H, 3.71; N, 17.13; S, 7.85.
2.1.4. 5-((3-Nitrophenyl) diazenyl) quinolin-8-ol (4d)
Gray color; yield 90%; Rf; 0.7, mp (°C); 278–280; UV–vis (λ max,
nm, methanol): 465; IR (KBr, γ, cm−1): 3432 (O—H str.), 1608 (C=C
str.), 1586, (C=N str. quinolinyl), 1506 (—N=N—), 1338 (NO2 str.),
934 (S—N str.); 1H NMR (DMSO-d6, δ ppm, 300 MHz): 8.10–8.66
(4H, aryl-H), 9.11 (d, quinolinyl H-2, J = 9.03 Hz), 7.78 (d, quinolinyl
H-3, J = 9.01 Hz), 8.33 (d, quinolinyl H-4, J = 8.09 Hz), 7.87 (d,
quinolinyl H-6, J = 8.09 Hz), 7.32 (d, quinolinyl H-7, J = 8.04 Hz);
LC–MS (% area); 93; m/z; 295.17 (M + 1); analysis for C15H10N4O3:
calcd % C, 61.22; H, 3.43; N, 19.04; found %: C, 61.25; H, 3.41;
N, 19.07.
2.1.5. 5-((2-Methoxyphenyl) diazenyl) quinolin-8-ol (4e)
Dark red color; yield 95%; Rf; 0.7, mp (°C); 257–260; UV–vis
(λ max, nm, methanol): 385; IR (KBr, γ, cm−1): 3356 (O—H str.),
2837 (CH2 str OCH3), 1597 (C=C str.), 1573 (C=N str. quinolinyl),
1501 (—N=N—), 1258 (OH bend.), 776 (1, 2 disubst. Ar—H); 1H
NMR (DMSO-d6, δ ppm, 300 MHz): 3.85 (s, 3H, OCH3), 6.70– 8.11
(4H, aryl-H), 9.21 (d, quinolinyl H-2, J = 9.01 Hz), 7.67 (d, quinolinyl
H-3, J = 9.02 Hz), 8.33 (d, quinolinyl H-4, J = 8.05 Hz), 7.91 (d,
quinolinyl H-6, J = 8.07 Hz), 7.26 (d, quinolinyl H-7, J = 8. 02 Hz);
LC–MS (% area); 80.95; m/z; 280.21 (M + 1); analysis for C16H13N3O2:
calcd % C, 68.81; H, 4.69; N, 15.05; found %: C, 62.84; H, 4.67;
N, 15.07.
2.1.6. 5-((4-Bromo-3-methylphenyl) diazenyl) quinolin-8-ol
(4f)
Dark red color; yield 97%; Rf; 0.8, mp (°C); 260–263; UV–vis
(λ max, nm, methanol): 390; IR (KBr, γ, cm−1): 3290 (O—H str),
2922 (CH2 str CH3), 1578 (C=N str. quinolinyl), 1503 (—N=N—),
621 (C—Br), 885 (1, 2, 4 trisubst. Ar—H); 1H NMR (DMSO-d6, δ
ppm, 300 MHz): 2.51 (s, 3H, CH3), 7.61–7.83 (3H, aryl-H), 8.91(d,
quinolinyl H-2, J = 9.0 Hz), 7.55 (d, quinolinyl H-3, J = 9.01 Hz),
8.11 (d, quinolinyl H-4, J = 8.03 Hz), 7.91 (d, quinolinyl H-6,
J = 8.01 Hz), 7.34 (d, quinolinyl H-7, J = 8.01 Hz); LC–MS (% area);
99.84; m/z; 342.18 (M + 1); analysis for C16H12BrN3O: calcd % C,
56.16; H, 3.53; N, 12.38; found %: C, 56.14; H, 3.55; N, 12.40.
2.1.7. 4-((8-Hydroxyquinolin-5-yl) diazenyl)-1, 5-dimethyl-2-
phenyl-1H-pyrazol-3(2H)-one (4g)
Gray color; yield 90%; Rf; 0.7, mp (°C); 261–265; UV–vis (λ max,
nm, methanol): 397; IR (KBr, γ, cm−1): 3370 (O—H str), 2923 (CH2
str. methyl), 1674 (C=O str. pyrazolone), 1581 (C=N str.
quinolinyl), 1541 (—N=N—), 1274 (C—O str.); 1H NMR (DMSO-
d6, δ ppm, 300 MHz): 2.50 (s, 3H, =C—CH3), 3.38 (s, 3H, N—CH3),
7.22–7.78 (m, 5H, aryl-H), 9.33 (d, quinolinyl H-2, J = 9.03 Hz), 7.79
(d, quinolinyl H-3, J = 8.03 Hz), 8.07 (d, quinolinyl H-4, J = 8.05 Hz),
8.11 (d, quinolinyl H-6, J = 8.08 Hz), 8.13 (d, quinolinyl H-7,
J = 8.08 Hz); LC–MS (% area) 78.11; m/z; 360.24 (M + 1); analysis
for C20H17N5O2: calcd % C, 66.84; H, 4.77; N, 19.49; found %: C,
66.81; H, 4.75; N, 19.51.
2.1.8. 2-((8-hydroxyquinolin-5-yl) diazenyl) benzoic acid (4h)
Dark red color; yield 90%; Rf; 0.8, mp (°C); 267–270; UV–vis
(λ max, nm, methanol): 392; IR (KBr, γ, cm−1): 3410 (O—H str.),
1690 (C=O str. carboxylic acid), 1592 (C=N str. quinolinyl), 1510
(—N=N—), 1241 (C—O str.), 722 (1, 2 disubst. Ar—H); 1H NMR
(DMSO-d6, δ ppm, 300 MHz): 8.11–8.61 (m, 4H, aryl-H), 9.13 (d,
quinolinyl H-2, J = 9.01 Hz), 7.72 (d, quinolinyl H-3, J = 9.03 Hz),
8.43 (d, quinolinyl H-4, J = 8.05 Hz), 8.01 (d, quinolinyl H-6,
J = 9.03 Hz), 7.51 (d, quinolinyl H-7, J = 8.03 Hz); LC–MS (% area)
100; m/z; 294.17 (M + 1); analysis for C16H11N3O3: calcd %: C, 65.53;
H, 3.78; N, 14.33; found %: C, 65.54; H, 3.77; N, 14.35.
2.2. Microbiology
2.2.1. Antimicrobial screening
The above newly synthesized oxychinolin hybrid analogs were
investigated over different bacterial strains viz. Escherichia coli
(MTCC 614), Salmonella enterica ser. typhi (MTCC 773), Salmo-
nella enterica typhimurium (MTCC 98), Salmonella enterica paratyphi
(MTCC 3220), Shigella flexneri (MTCC 1457), Pseudomonas aeruginosa
(MTCC 1035), Vibrio cholera (MTCC 3906), Klebsiella pneumoniae
(MTCC 109), Micrococcus luteus (MTCC 1809), Bacillus circulans
(MTCC 490), Streptococcus mitis (MTCC 2695) and Pectobacterium
carotovorum (MTCC 1428) were procured from the Institute of
Microbial Technology and Gene bank (IMTECH), Chandigarh,
India. Staphylococcus aureus and B. subtilis strain HSWX88 were
isolated in the Pharmaceutical Biotechnology Division of the
University Department of Pharmaceutical Sciences, Utkal Uni-
versity, Bhubaneswar, Odisha, India (Pradhan et al., 2013). The
microorganisms under test were freshly sub cultured on nu-
trient agar plates (Hi-Media) 24 h prior to the evaluation of
antimicrobial activity. Ampicillin was used as reference
antibiotic.
The antimicrobial activity of the novel oxychinolin analogs
was performed by well and plate method using molten
nutrient agar medium (Sahoo and Sudhir Kumar, 2015). After
solidification, the media were inoculated and punched in
to 6 mm diameter wells. The wells were filled with stock
solution of test and reference compounds (1μg μL−1 concen-
tration) and incubated for 24 h at 37 °C. The diameter of zone
of inhibition was measured using the Hi-Antibiotic Zone
Scale.
2.2.2. Determination of minimum inhibitory concentration
(MIC)
The lowest concentration of the antimicrobial agents those
inhibit the growth of the test organisms. It is not necessary
that they must kill the organisms. 1mgmL−1 stock solution of
synthesized compounds and reference antibiotic was pre-
pared using 10% DMF solution. Further, five different
concentrations of (500–31.25 μg ml−1) were prepared. Agar well
diffusion method and serial dilution assay procedure were em-
ployed to establish minimum inhibitory concentration. The
different concentrations for respective compounds were loaded
into the wells, and incubated at 37 °C for 18–24 h. After
234 b en i - s u e f un i v e r s i t y j o u rna l o f b a s i c and a p p l i e d s c i e n c e s 4 ( 2 0 1 5 ) 2 3 2 – 2 4 5
incubation the MIC of the synthesized compounds against the
bacterial strains was determined (Sahoo and Sudhir Kumar,
2015).
2.3. Pharmacological screening
2.3.1. Animals
In this work, male and female Wistar rats of 180–200 g (acute
toxicity study and wound healing activity) and Swiss Albino
mice of either sex, 25–30 g (analgesic evaluation) of appropri-
ate age were used. The experiments were carried under the
guidelines of Committee for the Purpose of Control and Su-
pervision of Experiments on Animals and approved by the
Institutional Animal Ethical Committee with registration
number 1171/C/08/CPCSEA and Ref. No. 60/SPS/IAEC/SOAU.
2.3.2. Acute toxicity study
Acute oral toxicity study was performed on female Wistar rats
to establish the safety dose of the synthesized compounds.
OECD guideline No.420 (2000) for Acute Oral Toxicity-Fixed dose
procedure was followed (sighting study and main study) for
a period of 14 days to study the acute toxic symptoms and the
behavioral changes within the animals.
2.3.3. Excision wound model
On the basis of in vitro antimicrobial evaluation of newly syn-
thesized oxychinolin (8-HQ) analogs, the test compounds (4c,
4e, 4g and 4h) showing significant antibacterial activity against
a maximum number of strains were selected for evaluation of
wound healing activity. For assessment of wound healing ac-
tivity wound excision model was followed using male Wistar
rats (Sahoo and Sudhir Kumar, 2015).The animals were divided
in to 10 groups, each carrying 6 animals. The acclimatized
animals were anesthetized by light ether anesthesia and the
cleaned skin surface with suitable depilatory was cut to create
circular wounds of (300 ± 15 mm2 maximum) area. The areas
of the fresh wound were measured by placing a transparent
polythene graph paper on it. Initial wound area was re-
corded. Group-1 served as control, group-2 was treated with
2% w/w nitrofurazone cream (standard) and remaining groups
(group 3–10) were treated with 5% and 10% w/w ointments con-
taining test compounds once a day for 16 days, topically. The
area of the wounds was recorded on 4th, 8th, 12th and 16th
day and % inhibition was calculated.
2.3.4. Incision wound model
Light incisions were made on the cleared surface by cutting
the skin of the animals under mild ether anesthesia (Sahoo
and Sudhir Kumar, 2015). The wounds were created at a length
of about 2 cm. after the incision; the parted skin was kept to-
gether and stitched with black silk at both the end of the created
wound. The test samples were applied as above in similar
manner. The tensile strength was measured by using tensi-
ometer on 16th post wounding day.
2.3.5. Acetic acid induced writhing model
Albino mice of appropriate weight of either sex were main-
tained under controlled environmental conditions of light and
temperature. The animals were divided in to 10 groups, each
carrying 6 animals. Group-1 was treated as control, group-2
served as positive control where they were administered with
standard diclofenac sodium at a dose of 10 mg/kg body weight,
intra-peritoneal. Groups (3–10) were provided with test (4c, 4e,
4g and 4h) compounds respectively at a dose level of 50 and
100 mg/kg body weights orally. All the groups were adminis-
tered with 0.6% v/v acetic acid solution at a dose level of 1 mL/
100 g of body weight intra-peritoneally, 30 min after
administration of diclofenac sodium in group 2 and 1 h after
administration of test drugs in group 3–10 (Jagtap and
Fernandes, 2008). The onset of writh was noted. Finally, % an-
algesic activity was calculated.
% Analgesic activity Mean writhing count Control group
Trea
= (
− ted group Mean writhing
count of control group
)
× 100.
The reaction time was expressed as mean ± SEM. The sta-
tistical analysis was done by one way- ANOVA followed by
Dunnett’s t- test.
2.3.6. Eddy’s hot plate model
Eddy’s hot plate (Techno) was used to induce pain by thermal
stimuli and to measure the response latencies as per method
first described by Eddy and Leimback (1953) with a little modi-
fication. The instrument was auto adjusted to 55 ± 0.5 °C of
temperature. The test was very useful for discriminating
between centrally acting morphine like analgesics and non-
opiate analgesics (Vogel, 2002). The latency for all the groups
was recorded before administration of the drug and 60, 120,
180, 240, 360 min after administration of the drug. The results
(reaction time) were expressed as mean ± SEM and one way-
ANOVA followed by Dunnett’s t-test was used for statistical
analysis. A cut of time period of 15 s was used to avoid any
thermal injury to the animals.
2.3.7. In vitro antioxidant activity
The free radical scavenging activity of novel oxychinolin (8-
HQ) analogs (4c, 4e, 4g and 4h) was measured by DPPH method
with some modification (Sahoo and Sudhir Kumar, 2015). The
antioxidant activity of synthesized compounds was com-
pared with standard butylated hydroxy toluene. Optical density
was measured at 517 nm and the inhibition concentration was
calculated. Solution of DPPH in methanol was considered as
control. All the experiments were carried out in triplicate and
IC50 values were expressed as mean ± SD.
% .of inhibition A A Acont test cont= ×−( )[ ] 100
A absorbance of controlcont. =
A absorbance of the test sample standardtest =
2.4. Statistical analysis
The observed data on zone of inhibition for different synthe-
sized compounds on different microbial strains were subjected
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to one way analysis of variance (ANOVA) for comparison of
mean.The mean zone of inhibition for each compound on each
strain was compared with the reference compound (RA) through
Dunnett’s post hoc test. The test of significance was done at
5% level of type one error. The research hypothesis was ‘the
zone of inhibition for test compound was higher than the ref-
erence antibiotic against the hypothesis of no difference (null
hypotheses)’ which states that there is no significant differ-
ence between the zone of inhibition of the test compound and
reference antibiotics.
2.5. Sample size determination
The minimum sample size determination was done for one
way analysis of variance with the help of the on line soft ware
https://www.statsdodo.com/SSizAOV_Pgm.php under the guid-
ance of a statistician. A minimum sample size of 5 was
calculated taking probability of type 1 error (d) = 0.05, power
(1 − β) = 0.8, number of groups 13 within group SD = 2. However
a sample size of 6 has been taken in the study for each com-
pound against each strain.
3. Results
3.1. Chemistry
3.1.1. Spectral characterization
The infrared spectra of the prepared compound starting ma-
terial oxychinolin (8-HQ) showed the broad absorption band
at 3203 cm−1 corresponding to —OH str group and band at 1605
and 1587 cm−1 with respect to C—N str and C—C str of 8-HQ
nucleus.The 1H NMR spectrum for 8-HQ showed heteroaromatic
peak at a range of δ 7.24–9.33 ppm. The infrared spectra of the
prepared compound 4b showed two strong broad absorption
bands at 3295 and 3150 cm−1 whereas 4c showed 3297 and
2847 cm−1 (Fig. 1) due to stretching vibration of hydroxyl group
of 8-HQ and due to intermolecular and intramolecular hydro-
gen bonding between hydroxyl group and nitrogen of quinoline
nucleus (Vinogradov and Elinson, 1979). Compound 4c showed
four strong absorption bands at 1506, 1341, 1170 and 934 cm−1
which were assigned to stretching —N=N—, asym/sym stretch-
ing of SO2 group and S—N str respectively. The FT/IR spectrum
of compound 4g showed two strong absorption bands at
1674 cm−1 and 1581 cm−1 due to the presence of the pyrazolone
carbonyl stretching and C—N str. of quinoline respectively. The
bands at 1690, 1510, 1592 and 1241 cm−1 indicate the pres-
ence of carbonyl stretching of carboxylic acid, —N=N—, C=N
str. of quinoline and C—O str. in compound 4h. In the 1H NMR
spectra of newly synthesized compounds (4a–h), the hetero aro-
matic protons of quinoline moiety appeared at δ 8.91–9.33
doublet (H-2), δ 7.55–7.79 ppm multiplet (H-3), δ 8.03–8.50 ppm
doublet (H-4), δ 7.80–8.11 ppm multiplet (H-6) and δ 7.26–
8.13 ppm doublet (H-7). Compound 4g showed a singlet peak
at δ 2.50 and δ 3.38 ppm respectively for N—CH3 and =C—CH3.
Compound 4c had singlet peaks at δ 6.28 ppm with respect to
substituted isoxazole proton and at δ 2.38 ppm for methyl
proton in the 1H NMR Spectra (Fig. 2). Compound 4c molecu-
lar ion peak 410.30 m/z strongly reveals the predicted molecular
formula C19H15N5O4S (Fig. 3).
3.1.2. Solvatochromic behavior
The absorption spectra of newly synthesized oxychinolin
analogs were measured with five solvents having different po-
larities (methanol, isopropanol, dimethyl sulfoxide, dimethyl
formamide and tetrahydrofuran with range of 200–500 nm at
a concentration of 10−3–10−5 M. Two distinct absorbance bands
were observed in all the solvents used for all the compounds.
The visible absorption spectra of compounds were found to
exhibit a moderate solvent dependence which did not show
a regular variation with the dielectric constant of solvents. The
relatively small difference observed is assumed to be caused
by solvent–solute interaction. According to UV analytical re-
ported data in Table 1. An azo linkage of meta nitro phenyl
Fig. 1 – FT/IR spectral data of compound 4c.
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substituent to 8-HQ at C-5 position gave the largest
bathochromic shift in all five solvents with respect to λmax in
compound 4d. The insertion of isoxazolyl substituent to 8-HQ
gave the bathochromic shift in all the solvents with respect
to λmax in compound 4c (Fig. 4).
3.2. Thermal analysis
The DSC thermogram reported sharp and narrow endother-
mic peak by compound 4c showed peak temperature at
221.02 °C corresponding to its melting point (Fig. 5).
Fig. 2 – 1H NMR of compound 4c.
Fig. 3 – LC–MS of compound 4c.
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3.3. Microbiology
3.3.1. Antimicrobial activity
Most of the synthesized oxychinolin analogs have effective an-
timicrobial activity.The mean ± SD of zone of inhibition for each
microbial strain has been compared by one way-analysis of vari-
ance and the resulting p value. The mean zone of inhibition
among the different compounds was found to be signifi-
cantly different with p value of 0.00.
The results of the antimicrobial activity of the newly syn-
thesized compounds compared with standard expressed in
mean ± SD were reported in Table 2.The reported results revealed
that the significant antimicrobial activities in comparison RA
(p < 0.05) showed by compound 2-((8-hydroxyquinolin-5-yl) diazenyl)
benzoic acid (4h) against Salmonella entericaparatyphi, Shigella
flexneri, Pseudomonas aeruginosa, Vibrio cholera, Klebsiella
pneumoniae, Micrococcus luteus, Bacillus circulans, Streptococcus mitis
and Bacillus subtilis were (19.17 ± 1.33), (22.67 ± 1.51), (21.83 ± 0.75),
(24.33 ± 1.97), (21 ± 2.19), (20.33 ± 1.75), (28 ± 0.63), (18.83 ± 1.17),
and (21.67 ± 1.75) respectively. Compound 4-((8-hydroxyquinolin-
5-yl) diazenyl)-1, 5-dimethyl-2-phenyl-1H-pyrazol-3(2H)-one (4g)
showed significant antimicrobial activities against Pseudomonas
aeruginosa, Vibrio cholera, Micrococcus luteus, Streptococcus mitis and
Bacillus subtilis as (20 ± 1.1), (18 ± 2), (18.5 ± 1.38), (20.67 ± 1.63) and
(19.83 ± 1.89) respectively.The significant antimicrobial activities
in comparison to RA exhibited by compound 4c against
Escherichia coli, Shigella flexneri, Pseudomonas aeruginosa, Vibrio
cholera, Streptococcus mitis and Bacillus subtilis were (20 ± 2),
(21 ± 1.27), (27.17 ± 1.33), (26 ± 1.79), (23 ± 1.41) and (18.17 ± 2.32)
respectively in comparison to RA. Among all the tested com-
pounds, the compound 4h showed excellent, 4c and 4g good
and 4a, 4b, 4d and 4f showed moderate significant antibacte-
rial activity. However, the excellent significant antibacterial
activity showed by compound 4h may be due to the presence
of anthranilyl entity attached at C-5 position of oxychinolin.The
zones of inhibitions of few azo oxychinolin analogs were pre-
sented in Fig. 6. The significant antimicrobial activity of
compounds 4g and 4h is interpreted graphically by the help of
error bars in Fig. 7.
3.3.2. Minimum inhibitory concentration (MIC)
The inhibitory property of the 8-HQ analogs was determined
in terms of MIC (μg mL−1) within concentration range of
500–31.25 μg mL−1. The MIC values of the test analogs against
different bacterial strains were investigated to determine the
minimum level of concentration at which the compound is able
to exert its activity (Table 3). Compounds 4g and 4h showed
excellent antibacterial activity against all the bacterial strains
included in the test at minimum concentration level of
31.25 μg mL−1. Compounds 4a, 4b, 4c and 4f exhibited poor
Table 1 – UV–Vis spectral data (λmax) of newly synthesized azo oxychinolin derivatives (4a–h).
Compds. λ max (isopropanol) λ max (methanol) λ max (DMSO) λ max (DMF) λ max (THF)
4a 399 243,398 411 293,398 398
4b 390 243,391 407 395 241,385
4c 243,404 243.403 412 407 404
4d 479 242,334, 465(W) 463 438 418
4e 248,386 385 406 405 388
4f 246,390 245,390 409 405 393
4g 246,399 248,397 410 409 405
4h 245,400 243,392 411 403 400
Fig. 4 – Solvatochromism of 4c using different solvents (a) and azo oxychinolin derivatives using THF (b).
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antibacterial activity with a minimum concentration level of
125 μgmL−1 against Salmonella enterica ser. typhi and Salmonella
entericaparatyphi. The reported antibacterial activity against Es-
cherichia coli and Salmonella enterica ser. typhi by compound 4d
is at minimum concentration level of 500 μgmL−1.The compound
4e is also exhibited with antibacterial activity at 500 μgmL−1.
The reference antibiotic showed its antibacterial activity against
all the organisms that participate in the experiment at MIC level
of 31.25 μg mL−1.
3.4. Pharmacology
3.4.1. Acute toxicity
The acute toxicity study revealed that there was no mortality
in all the test compounds within 14 days of observation. The
synthesized compounds were safe up to 2000 mg/kg body
weight. No toxic symptoms and gross behavioral changes were
found to be observed in the animals.
3.4.2. Wound healing activity
In the excision wound model, the wound recovered (contrac-
tion) progressively by the end of 16 days of observation. The
results expressed mean ± SEM and obtained data analyzed by
Dunnett’s t test using one way ANOVA (Table 4). The optimum
healing evidenced by minimum area of wound remained or %
inhibition by 16 days of observation for the subjected com-
pounds along with standard. The compounds included in the
experiment were reported with significant wound healing
activity with more than 80% of wound inhibition by the end
of 16 days. The remaining area of wound for the newly
synthesized oxychinolin analogs were found to be 4g
(43.1 ± 5.6 mm2) with a 89.32% inhibition and 4h (51.3 ± 3.1 mm2)
with a 83.26% inhibition at a concentration level of 5% test
compound and similarly 4g (42 ± 5.3 mm2) with a 86.37% in-
hibition and 4h (48.6 ± 3.5 mm2) with a 87.54% inhibition at a
concentration level of 10% test compound. The remaining area
of wound for control was 68 ± 5.8 mm2 and standard was
34.6 ± 5 mm2 with 88.71% inhibition. The progressive wound
healing by compound 4g is reported in Fig. 8.
In incision study 4e (10%), 4g (5%), 4g (10%), 4h (5%) and 4h
(10%) showed 376.1 ± 69 g, 363.3 ± 4.7 g, 378 ± 7.2 g, 365.8 ± 8.5 g
and, and 404.6 ± 5.9 g breaking strength respectively which are
significantly increased in comparison to control 328.6 ± 8.6 g
(Table 4).
3.4.3. Analgesic activity
In control group acetic acid produced an average of 83.16 ± 2.18
writhes in 10 min of observation. Standard diclofenac sodium
(10 mg/kg) showed % of inhibition with 63.2% while the newly
synthesized 8-HQ hybrid analogs (4c, 4e, 4g and 4h) (100 mg/kg
body weight) observed with 20.23%, 24.84%, 40.68% and 50.5%
of inhibition respectively among which 8-HQ analogs bearing
pyrazolone and anthranilic acid derivative (4h and 4g) re-
ported with highest % of inhibition (50.5 and 40.68%) respectively
(Table 5). However the compound 4g showed significant writh-
ing response in both (50 and 100 mg/kg body weights) the
doses.
In hot plate model the control group animal showed
3.60 ± 0.44 s of reaction time while the compound 4h showed
highly significant analgesic activity by the end of 1 h and 2 h
for a reaction time of 10.21 ± 0.79 and 9.2 ± 1.30 (p < 0.05). Com-
pound 4g evidenced with reaction time of 7.05 ± 0.87 (p < 0.05)
and 7.91 ± 1.30 (p < 0.01) by the end of 1 h and 2 h respec-
tively. While compound 4c reported with 8.18 ± 0.49 and
8.73 ± 1.21 (p < 0.01) and 4e reported with 7.3 ± 1.09 and
7.58 ± 1.09 (p < 0.01) reaction time by the end of 2 h and 3 h
Fig. 5 – DSC of compound 4c.
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Table 2 – Antimicrobial activity (zone of inhibition in mm) of newly synthesized azo oxychinolin (4a–h) derivatives
against different bacterial strains (mean ± S.D.).
Compds. Eca Seb Stc Spd Sfe Paf Vcg
4a 15 ± 1.67 11 ± 2.19 16 ± 2.61 12 ± 0.63 17 ± 1.41 15 ± 1.41 14.83 ± 1.33
4b 12 ± 1.27 10 ± 1.79 12.17 ± 1.6 10.33 ± 0.52 15 ± 1.67 18.33 ± 1.75 23 ± 2.19*
4c 20 ± 2* 12.17 ± 1.17 17.33 ± 1.03 8.67 ± 1.21 21 ± 1.27* 27.17 ± 1.33* 26 ± 1.79*
4d 9.67 ± 1.51 9.67 ± 1.51 – 10.17 ± 1.33 8.83 ± 1.33 21 ± 1.79* 10.83 ± 1.6
4e 11.17 ± 1.17 – – 9 ± 1.27 12.33 ± 1.63 17.17 ± 1.33 16.17 ± 1.47
4f 11.5 ± 0.84 13.33 ± 1.51 – 13.67 ± 0.82 13.83 ± 1.6 21.83 ± 0.75* –
4g 16.83 ± 0.75 14.17 ± 0.75 18.67 ± 1.21 14 ± 0.63 18.83 ± 1.33 20 ± 1.1* 18 ± 2
4h 18 ± 2.97 15.5 ± 1.23 14 ± 0.63 19.17 ± 1.33* 22.67 ± 1.51 21.83 ± 0.75* 24.33 ± 1.97*
RA 16 ± 1.1 23.17 ± 1.33 18.33 ± 1.37 16 ± 1.67 18 ± 0.89 17.17 ± 1.33 14 ± 0.63
Total 14.46 ± 3.68 13.62 ± 4.34 16.08 ± 2.77 12.56 ± 3.48 16.39 ± 4.35 19.94 ± 3.63 18.4 ± 5.39
ANOVA ‘p’ value 0 0 0 0 0 0 0
Compds. Kph MLi Bcj Smk Pcl Bsm San
4a 14.17 ± 1.94 17 ± 2.1* 14.33 ± 1.21 15 ± 1.67* 15.17 ± 1.94 17.17 ± 1.17 17.17 ± 1.47
4b 15.17 ± 1.94 12 ± 2.1 15 ± 2.19 12.17 ± 0.41 10.5 ± 1.64 12.17 ± 1.17 11.17 ± 1.33
4c 15.83 ± 1.17 16.17 ± 2.23 16.5 ± 1.05 23 ± 1.41* 19 ± 1.27 18.17 ± 2.32* 25.33 ± 1.97
4d – 14.33 ± 1.03 – 10.67 ± 1.51 12.33 ± 1.21 12.67 ± 1.51 –
4e 12.5 ± 0.55 11.67 ± 0.82 – 15 ± 0.63 12.83 ± 1.17 14 ± 2 –
4f 21.17 ± 0.98* 11.5 ± 0.84 – 16.33 ± 1.75* 10.33 ± 2.07 11.83 ± 0.98 –
4g 18 ± 0.63 18.5 ± 1.38* 26.33 ± 0.52 20.67 ± 1.63* 14.5 ± 1.38 19.83 ± 1.84* 21.33 ± 2.34
4h 21 ± 2.19* 20.33 ± 1.75* 28 ± 0.63* 18.83 ± 1.17* 22 ± 1.67 21.67 ± 1.75* 16 ± 2.83
RA 17 ± 2.19 14.17 ± 0.41 25.17 ± 1.94 13 ± 1.79 23 ± 3.03 15 ± 1.27 25.17 ± 2.71
Total 16.85 ± 3.28 15.07 ± 3.32 20.89 ± 5.93 16.07 ± 4.09 15.52 ± 4.82 15.83 ± 3.69 19.36 ± 5.56
ANOVA ‘p’ value 0 0 0 0 0 0 0
Results expressed in mean ± S.D. (n = 6). The data were analyzed by One Way ANOVA followed by Dunnett’s post hoc test (statistical signifi-
cance at *p < 0.05 in comparison to RA: ampicillin).
–: No zone of inhibition.
a Escherichia coli.
b Salmonella enterica ser. typhi.
c Salmonella entericatyphimurium.
d Salmonella entericaparatyphi.
e Shigella flexneri.
f Pseudomonas aeruginosa.
g Vibrio cholera.
h Klebsiella pneumoniae.
i Micrococcus luteus.
j Bacillus circulans.
k Streptococcus mitis.
l Pectobacterium carotovorum.
m Bacillus subtilis.
n Staphylococcus aureus.
Fig. 6 – Antimicrobial activity of compounds 4e, 4f, 4g and 4h against S. flexneri (a), V. cholera (b) and S. enteroser. typhi (c).
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respectively. Maximum order of % of inhibition of pain ob-
served between pre and post administration of drug was found
in compounds 4h (30.55%), 4g (20.00%), 4e (17.77%), 4c (13.61%)
at a dose of 100 mg/kg body weight and for standard (54.16%).
However, in both acetic acid induced writhing and hot plate
model compounds 4h and 4g respectively reported with better
% of inhibition and significant analgesic activity. The results
of the test compounds administered at doses of 50 and
100 mg/kg are reported in Table 5.
3.4.4. Antioxidant activity
DPPH radicals accept the hydrogen atom or electron from the
organic molecules and can form stable dimagnetic mol-
ecules. Scavenging effect of newly synthesized compounds 4c,
4e, 4g and 4h showed good antioxidant activity. The test com-
pounds 4c, 4e, 4g and 4h and the standard reported with 50%
of inhibition (IC50) at a concentration levels of 52 ± 1.13, 72 ± 1.4,
36 ± 0.56, 46 ± 0.98 and 31 ± 0.07 μg/mL respectively. The results
of antioxidant activity of the selected oxychinolin analogs are
Fig. 7 – Graphical interpretation of significant antimicrobial activity of compounds 4g and 4h.
Table 3 – Minimum inhibitory concentration MIC (μg/mL) of synthesized azo oxychinolin derivatives (4a–h).
Compds. Eca Seb Stc Spd Sfe Paf Vcg Khh Mli Bcj Smk Pcl Bsm San
4a 31.25 125 31.25 125 31.25 31.25 62.5 62.5 31.25 62.5 31.25 31.25 31.25 31.25
4b 62.5 125 31.25 125 31.25 31.25 31.25 31.25 62.5 31.25 62.5 125 62.5 125
4c 31.25 125 31.25 125 31.25 31.25 31.25 31.25 31.25 31.25 31.25 31.25 31.25 31.25
4d >500 >500 – 62.5 125 31.25 62.5 – 31.25 – 125 125 125 –
4e 125 – – >500 62.5 31.25 31.25 31.25 62.5 – 31.25 125 31.25 –
4f 125 125 – 125 125 31.25 – 31.25 125 – 31.25 125 125 –
4g 31.25 31.25 31.25 31.25 31.25 31.25 31.25 31.25 31.25 31.25 31.25 31.25 31.25 31.25
4h 31.25 31.25 31.25 31.25 31.25 31.25 31.31.25 31.25 31.25 31.25 31.25 31.25 31.25 31.25
RA 31.25 31.25 31.25 31.25 31.25 31.25 31.25 31.25 31.25 31.25 31.25 31.25 31.25 31.25
–: No zone of inhibition.
RA, reference antibiotic: ampicillin.
a Escherichia coli.
b Salmonella enterica ser. typhi.
c Salmonella entericatyphimurium.
d Salmonella entericaparatyphi.
e Shigella flexneri.
f Pseudomonas aeruginosa.
g Vibrio cholera.
h Klebsiella pneumoniae.
i Micrococcus luteus.
j Bacillus circulans.
k Streptococcus mitis.
l Pectobacterium carotovorum.
m Bacillus subtilis.
n Staphylococcus aureus.
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reported in Table 6 and Fig. 9. The pyrazolone (4g) and
anthranilyl (4h) substituted azo oxychinolin analogs showed
better antioxidant activity and others showed moderate activity.
4. Discussion
As indicated in Table 1, compounds 4d (3-nitro phenyl substi-
tuted 8-HQ) and 4h (2-carboxy phenyl substituted 8-HQ),
introduction of electron withdrawing groups at phenyl ring
showed bathochromic shift of 463 nm and 411 nm respec-
tively in DMSO, relatively to compound 4e (2-methoxy phenyl
substituted 8-HQ) containing electron donating group at phenyl
ring showed λmax at 406 nm.This indicates that the analogs con-
taining both electron donor and electron acceptor terminal
group compound 4f (4-bromo,3-methyl phenyl substituted 8-HQ)
showed bathochromic shift at 409 nm in comparison with the
compound 4e which have only electron donor group
(Yazdanbakhsh and Mohammadi, 2009).
On the basis of antimicrobial studies, out of eight newly syn-
thesized azo based oxychinolin analogs, the compounds (4c,
4g and 4h) showed significant antimicrobial activity against
a maximum number of bacterial strains may be considered as
excellent. The significant antimicrobial activity of the synthe-
sized compounds 4c, 4g and 4h may be due to the structural
presence of isoxazolyl, pyrazolone and 2-carboxy phenyl. The
compounds 4c, 4e, 4g and 4h were subjected for evaluation of
their wound healing and antioxidant activity. Reactive oxygen
species secreted at the site of wound is responsible for delayed
healing, on the other hand the presence of invasive microor-
ganisms and free radicals also hinders the healing process
(Houghton et al., 2005; Sheeba et al., 2009). The mechanism of
antioxidants is to terminate the formation of free radical in-
termediates and enable quick recovery. In general, phenolic
compounds and nitrogen bearing heterocyclic rings have free
radical scavenging activity (Chinnagiri et al., 2013). Com-
pounds 4g and 4h showed potential antioxidant activity and
posses nitrogen bearing heterocyclic ring and phenolic-OH
group respectively.The newly synthesized compounds showing
good wound healing activity also exhibited excellent antimi-
crobial property and potential radical scavenging activity. The
progressive percentage of inhibition area of the wound ob-
served in regular interval justified the above discussion.
The newly synthesized azo based oxychinolin (8-HQ) de-
rivatives were reported as analgesic agents. Literature survey
reveals that quinoline derivatives possess analgesic activity
(Anuradha et al., 2014). The side chain functional groups in-
cluding anthranilic acid (mephenamic acid and enphenamic
acid) and pyrazolone derivatives (analgin and metamizol) were
established chemical class of analgesics (Tripathi, 2004). On the
basis of above information, the analgesic activity of 8-HQ
analogs is screened by different models. The reported results
of acetic acid induced writhing model of selected compounds
showed significant inhibition of writhing response in mice.
Particularly, the compounds 4g and 4h showed highly signifi-
cant analgesic activity.The percentage of inhibition of writhing
for compounds 4g and 4h was 40.68% and 50.5% respectively
Table 4 – Wound healing activity of azo oxychinolin analogs by excision model and incision wound model.
Excision wound model Incision model
Compds. 0 day 4th day 8th day 12th day 16th day % inhibition Tensile strength (g)
Control 308.5 ± 5.9 213.5 ± 8.4 173.5 ± 6.1 138.8 ± 4.8 68 ± 5.8 77.95 328.6 ± 8.6
Standard (nitro furazone 2%) 306.6 ± 4.5 186 ± 7.3** 110.5 ± 4.8*** 76.1 ± 5.7*** 34.6 ± 5*** 88.71 538.3 ± 7.03***
4c (5%) 311.1 ± 6.6 206 ± 4.1 167.1 ± 5.9 113 ± 5.9* 46.5 ± 3.5* 85.05 331.1 ± 6.7
4c (10%) 306.3 ± 7.6 193 ± 4.6 149.6 ± 5.6* 89.3 ± 7.3*** 45.3 ± 5.5** 85.21 335.1 ± 7.5
4e (5%) 314.5 ± 7.3 201 ± 4.4 174.3 ± 7.8 137 ± 6.4 59.3 ± 4.7 81.14 347.6 ± 6.3
4e (10%) 308.1 ± 6.4 207 ± 6.6 172.3 ± 7.5 132.6 ± 7.4** 57 ± 3.8 81.49 376.1 ± 6.9***
4g (5%) 310 ± 7.8 207.3 ± 4.8 166.3 ± 6.4 110.6 ± 5.7** 43.1 ± 5.6** 89.32 363.3 ± 4.7**
4g (10%) 308.3 ± 6.2 196.3 ± 4.3 131 ± 5.9** 85 ± 8.1*** 42 ± 5.3** 86.37 378 ± 7.2***
4h (5%) 306.5 ± 6.7 213.3 ± 6.2 172.3 ± 6.6 129.1 ± 8.3* 51.3 ± 3.1* 83.26 365.8 ± 8.5**
4h (10%) 310 ± 6.9 207.6 ± 4.2 151.5 ± 7.8 115.3 ± 8** 48.6 ± 3.5* 87.54 404.6 ± 5.9***
Values are expressed in mean ± S.E.M; df = 9, 50 (n = 6); one way ANOVA followed by Dunnett’s t-test.
F-value denotes statistical significance at *p < 0.05, **p < 0.01, ***p < 0.001 in comparison to control (group-I).
Fig. 8 – Wounds treated with compound 4g showed progressive healing on 0 (a), 12 (b) and 16 (c) day.
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Table 5 – Analgesic effect of newly synthesized azo oxychinolin analogs on acetic acid induced writhing response and hot plate model.
Compds. Group Dose
(mg/kg
body wt.)
Acetic acid induced writhing response Hot plate method
Writhing response (s) % of inhibition 0th h 1st h 2nd h 3rd h 4th h 6th h % of inhibition F
Control
(distilled water)
1 83.16 ± 2.18 – – – – – – – – –
Standard
(diclofenac
sodium)
2 10 30.5 ± 2.52*** 63.32 3.60 ± 0.23 10.05 ± 1.37** 11.61 ± 1.11*** 8.78 ± 0.63* 6.88 ± 1.54 5.55 ± 0.76 54.16 8.06
4c 3 50 70.35 ± 6.36* 15.40 3.60 ± 0.36 3.88 ± 0.52 4.00 ± 0.32 6.61 ± 0.46** 3.90 ± 0.33 3.80 ± 0.64 5.55 6.11
4c 4 100 66.33 ± 4.94** 20.23 3.60 ± 0.04 8.18 ± 0.44** 8.73 ± 1.21** 7.17 ± 0.90* 4.91 ± 0.81 4.09 ± 1.02 13.61 6.87
4e 5 50 66.10 ± 6.48* 20.51 3.60 ± 0.44 3.93 ± 0.27 6.87 ± 0.83*** 4.71 ± 0.50 4.15 ± 0.18 3.97 ± 0.12 10.27 6.80
4e 6 100 62.50 ± 4.48** 24.84 3.60 ± 0.44 4.77 ± 0.76 7.3 ± 1.09** 7.58 ± 0.84** 4.39 ± 0.78 4.24 ± 0.35 17.77 5.02
4g 7 50 56.03 ± 0.19*** 32.62 3.60 ± 0.28 6.83 ± 0.83** 7.20 ± 0.78** 6.08 ± 0.60* 4.42 ± 0.47 4.20 ± 0.16 16.66 6.79
4g 8 100 49.33 ± 1.96*** 40.68 3.60 ± 0.28 7.05 ± 0.87* 7.91 ± 1.30** 7.52 ± 1.21** 4.69 ± 0.55 4.32 ± 0.24 20.00 4.71
4h 9 50 47.99 ± 0.95*** 42.29 3.60 ± 0.36 4.98 ± 1.28** 8.87 ± 0.71** 4.49 ± 1.148 4.53 ± 0.59 4.41 ± 0.79 22.5 4.60
4h 10 100 41.16 ± 3.72*** 50.50 3.60 ± 0.04 10.21 ± 0.79* 9.2 ± 1.30* 7.5 ± 1.24* 5.15 ± 1.19 4.7 ± 1.38 30.55 5.85
For acetic acid induced writhing model and hot plate model df = 9, 50; n = 6, values are expressed mean ± SEM. Values in 0 h are compared with 1, 2, 3, 4 and 6 h. The data were analyzed by One
Way ANOVA followed by Dunnett’s t-test.
F-value denotes statistical significance at *p < 0.05, **p < 0.01, ***p < 0.001 in comparison to control.
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where as for standard 63.32% at a dose of 100 mg/kg body
weight.
The hot plate method is used to evaluate the centrally acting
analgesics. Such drugs elevate the pain threshold toward heat.
Release of bradykinin by stimulation of heat is a major cause
of pain (Tripathi, 2004). In hot plate model, the newly synthe-
sized azo based 8-HQ analogs (4e, 4g and 4h) were reported
with significant increase of reaction time.
From the above results and discussion it was concluded that
the exploitation of 8-HQ or oxychinolin with various
functionalities have satisfactory antimicrobial, wound healing,
and analgesic activities among which pyrazolone and anthra-
nilic acid substituted 8-HQ congeners (4g and 4h) exhibited
significant results.
Corroborate to the findings of the earlier researchers it was
found that the azo oxychinolin derivatives have potential an-
tioxidant and antimicrobial activity whereas our synthesized
oxychinolin derivatives have significant biological potentiality.
5. Conclusion
Oxychinolins are popular for their biological properties; hence,
syntheses of azo oxychinolin with different functionalities are
the sphere of current research. The oxychinolin derivatives 4a–
4h was successfully synthesized, characterized and exhibited
broad spectrum antibacterial activities. The molecules even
proved to have significant wound healing, analgesic and an-
tioxidant activity. However, the azo oxychinolin compounds
attached with isoxazolyl (4c), pyrazolone (4g) and 2-carboxy
phenyl (4h) chemical entities showed better significant bio-
logical activities than other compounds.
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Table 6 – Antioxidant activity of azo oxychinolin analogs by DPPH scavenging model.
Compds Conc. μg/mL
10 30 50 70 IC50
% Inhibition
4c 19.26 ± 0.04 38.53 ± 0.09 48.33 ± 0.07 79.89 ± 0.06 52 ± 1.13
4e 17.96 ± 0.03 29.54 ± 0.05 33.64 ± 0.09 56.39 ± 0.08 72 ± 1.4
4g 29.72 ± 0.07 43.32 ± 0.11 63.44 ± 0.07* 83.02 ± 0.06 36 ± 0.56
4h 31.24 ± 0.06 41.31 ± 0.02 51.77 ± 0.08 79.89 ± 0.04 46 ± 0.98
BHT 32.32 ± 0.01 49.54 ± 0.01 59.99 ± 0.10 87.74 ± 0.06 31 ± 0.70
Results expressed in Mean ± SD, (n = 3), the data were analyzed by One Way ANOVA followed by Dunnett’s Post Hoc test (statistical signifi-
cance at *p < 0.05 in comparison to standard).
Fig. 9 – Antioxidant activity of azo oxychinolin analogs (4c, 4e, 4g, 4h) and their graphical interpretation.
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